$ARMP News
Last published 1mo ago
- 1mo agoARMPArmata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 1mo agoARMPArmata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 1mo agoARMPArmata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 1mo agoARMPArmata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 2mo agoARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 2mo agoARMPArmata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation AntibacterialsPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 3mo agoARMPArmata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate UpdatePR NewswireLOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity,
- 3mo agoARMPArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 4mo agoARMPArmata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus BacteremiaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 4mo agoARMPArmata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 6mo agoARMPArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 6mo agoARMPArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 6mo agoARMPArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 6mo agoARMPArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of DirectorsPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 7mo agoARMPArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial ResultsPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 7mo agoARMPArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 8mo agoARMPArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 10mo agoARMPArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureusPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the...
- 11mo agoARMPArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am ESTPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 12mo agoARMPArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, CaliforniaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular BiologyPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus BacteremiaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 1y agoARMPArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPINVAArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with InnovivaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy SummitPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 1y agoARMPArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity...
- 1y agoARMPArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual MeetingPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific...
- 1y agoARMPArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific...
- 1y agoARMPArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific...
- 2y agoARMPArmata Pharmaceuticals Announces Structural Biology PublicationPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 2y agoARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 2y agoARMPArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research SymposiumPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 2y agoARMPArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial OfficerPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 2y agoARMPArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific...
- 2y agoARMPArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity,...
- 2y agoARMPArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific...
- 2y agoARMPArmata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024PR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of...
- 2y agoARMPArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific...
- 2y agoARMPArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific...
- 2y agoARMPINVAArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...
- 2y agoARMPArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitPR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...
- 2y agoARMPArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdatePR NewswireArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage...
- 3y agoARMPINVAInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness WireReceived GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and